| P/E (FY) | 0.0 | Sales (TTM) | €109.7M |
| Earnings (TTM) | €17.4M | ROE | 15.66% |
| Net Margin | 15.88% | ROIC | 20.26% |
| Debt / Equity | 0.05 | TD / EBITDA | 0.20 |
| EPS Growth 3Y | −7.14% | Sales Growth 3Y | 4.19% |
Revenio Group Oyj supplies ophthalmological devices and software used to diagnose glaucoma, macular degeneration, and diabetic retinopathy. Its products include iCare tonometers for measuring intraocular pressure in human and animal patients, retinal imaging devices such as EIDON, DRSplus, and COMPASS, and software including the AI-based ILLUME screening tool, the CLINIC cloud platform, and the Oculo eye-care platform for telehealth and remote monitoring. The company operates in Finland, the United States, and other markets.
| Market Cap | — | Trading Days | 4112 |
| 52W High | 29.10 |
| 52W Low | 11.86 |
| % Off High | −56.43% |
| YTD | −43.39% | 1Y | −56.43% |
| 3Y | −58.27% | 5Y | −79.82% |
| 10Y | 78.91% | Since incept. (ann.) | 18.17% |
| Ann. Volatility (1Y) | 30.66% | Ann. Volatility (3Y) | 37.14% |
| Sharpe (1Y) | −2.51 | Sharpe (3Y) | −0.66 |
| Max Drawdown (1Y) | −59.18% | Max Drawdown (3Y) | −66.15% |
| Beta (3Y, vs SPY) | 0.16 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.14T | 52.7 |
| JNJ | JOHNSON & JOHNSON | $639.90B | 24.1 |
| ONC | BeOne Medicines Ltd. | $472.90B | 1722.2 |
| ABBV | AbbVie Inc. | $465.20B | 111.6 |
| MRK | Merck & Co., Inc. | $321.97B | 17.9 |
| AMGN | AMGEN INC | $209.21B | 27.2 |
| ABT | ABBOTT LABORATORIES | $188.12B | 29.0 |
| GILD | GILEAD SCIENCES, INC. | $164.79B | 19.6 |
| PFE | PFIZER INC | $143.34B | 18.5 |
| SYK | STRYKER CORP | $135.04B | 41.9 |
| BMY | BRISTOL MYERS SQUIBB CO | $128.90B | 18.2 |
| ISRG | INTUITIVE SURGICAL INC | $124.74B | 44.9 |
